Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma
Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma
Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma
SAMPLE FOR NHLTT VIDEOS (links on transcription)
SAMPLE FOR NHLTT VIDEOS (links on transcription)
Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma
75 yo w/ MSS T3 (1/20 node pos) tumor
75 yo w/ MSS T3 (1/20 node pos) tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?
Would you offer an Oncotype DX assay for an otherwise healthy 75-year-old patient with a Grade II, MSS T3 (1 out of 20 nodes positive) tumor?
If not, what adjuvant systemic therapy would you likely recommend for this patient?
60 yo w/ MSS T4N0 tumor
60 yo w/ MSS T4N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?
Would you offer an Oncotype DX assay for an otherwise healthy 60-year-old patient with a Grade II, MSS T4N0 (0 out of 20 nodes positive) tumor?
If not, what adjuvant systemic therapy would you likely recommend for this patient?
60 yo w/ MSS T3N0 tumor
60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?
Would you offer an Oncotype DX® assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor?
If not, what adjuvant systemic therapy would you likely recommend for this patient?
75 yo w/ MSS T3 (1/20 node pos) tumor
75 yo w/ MSS T3 (1/20 node pos) tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?
Would you offer an Oncotype DX assay for an otherwise healthy 75-year-old patient with a Grade II, MSS T3 (1 out of 20 nodes positive) tumor?
If not, what adjuvant systemic therapy would you likely recommend for this patient?
Consensus or Controversy, Issue 4: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Adjuvant Treatment of Colorectal Cancer
60 yo w/ MSS T3N0 tumor
60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?
Would you offer an Oncotype DX assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor?
If not, what adjuvant systemic therapy would you likely recommend for this patient?
Hematologic Oncology Update, Issue 3, 2013
OVERVIEW OF ACTIVITY
Recommended Obinutuzumab and Rituximab Dosing
Recommended Obinutuzumab and Rituximab Dosing
The recommended dose and schedule of obinutuzumab for the approved regimen with chlorambucil in CLL is:
Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2 and 1,000 mg on days 8 and 15
Cycles 2-6: 1,000 mg administered intravenously every 28 days
The recommended dose and schedule of rituximab for the approved regimen with fludarabine and cyclophosphamide (FC) in CLL is:
375 mg/m2 the day prior to the initiation of FC chemotherapy, then 500 mg/m2 on day 1 of cycles 2-6 (every 28 days)
5MJCHEM2013/4/
OVERVIEW OF ACTIVITY